EGFR and non-small cell lung carcinoma: In a single-arm phase II trial, the EGFR-inhibitor erlotinib was applied in patients with stage IA-IIIA NSCLC with EGFR-mutation after surgery, which resulted in an increased 2-year survival and a block of recurrence during the period of drug application, so that recurrence was delayed in most cases until treatment was discontinued (58).